Veeva Systems, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stan Berenshteyn from Wells Fargo maintained a Buy rating on the stock and has a $300.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stan Berenshteyn has given his Buy rating due to a combination of factors that highlight Veeva Systems’ strategic positioning and growth potential. The integration of Crossix into multi-brand master services agreements enhances Veeva’s ability to retain and upsell to major biopharma clients, leveraging its CRM and Crossix products. This wide adoption is expected to increase Veeva’s market share significantly.
Moreover, Crossix’s competitive edge is strengthened by its comprehensive data partnerships, privacy compliance, and seamless integration with Veeva’s broader technology stack. The anticipated growth in the DTC-facing pharma analytics market, driven by vendor consolidation and demand for compliance and ROI measurement, further supports Veeva’s growth prospects. Additionally, the rollout of Campaign Manager on Veeva’s Vault CRM is expected to provide a competitive advantage by closing the ‘insight-to-action’ loop, enhancing client go-to-market strategies.
According to TipRanks, Berenshteyn is an analyst with an average return of -1.6% and a 53.54% success rate. Berenshteyn covers the Healthcare sector, focusing on stocks such as Omnicell, Healthequity, and Veeva Systems.